Ausgabe 2/2006
Inhalt (8 Artikel)
Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience
Pierpaolo Correale, Maria Grazia Cusi, Lucia Micheli, Cristina Nencini, Maria Teresa del Vecchio, Francesco Torino, Angelo Aquino, Enzo Bonmassar, Guido Francini, Giorgio Giorgi
Novel in vitro model barriers for evaluation of the permeability of antitumor compounds, thioxanthones
Venugopal Marasanapalle, Xiaoling Li, Lisa Polin, Bhaskara R. Jasti
Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies
Cheryl D. Cho, George A. Fisher, Joanne Halsey, Branimir I. Sikic
A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers
Sanjay Goel, Kavita Desai, Manuel Macapinlac, Scott Wadler, Gary Goldberg, Abbie Fields, Mark Einstein, Fabio Volterra, Benny Wong, Russell Martin, Sridhar Mani
Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma
Elisabeth I. Heath, Barbara A. Burtness, Lawrence Kleinberg, Ronald R. Salem, Stephen C. Yang, Richard F. Heitmiller, Marcia I. Canto, Jonathan P. S. Knisely, Mark Topazian, Elizabeth Montgomery, Nancy Tsottles, Yazdi Pithavala, Bridget Rohmiller, Mary Collier, Arlene A. Forastiere
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma
Amy C. Peterson, Helena Harlin, Theodore Karrison, Nicholas J. Vogelzang, James A. Knost, John W. Kugler, Eric Lester, Everett Vokes, Thomas F. Gajewski, Walter M. Stadler
Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial
Toshiyuki Sawa, Takashi Yana, Minoru Takada, Takahiko Sugiura, Shinzoh Kudoh, Tadashi Kamei, Takeshi Isobe, Hidehiko Yamamoto, Soichiro Yokota, Nobuyuki Katakami, Yuji Tohda, Akira Kawakami, Yoichi Nakanishi, Yutaka Ariyoshi
Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: A National Cancer Institute of Canada Clinical Trials Group investigational new drug study
Eric Winquist, Jennifer Knox, Jean-Pierre Ayoub, Lori Wood, Nancy Wainman, Gregory K. Reid, Laura Pearce, Ajit Shah, Elizabeth Eisenhauer